Drug repurposing using transcriptome sequencing and virtual drug screening in a patient with glioblastoma
- PDF / 3,055,108 Bytes
- 16 Pages / 595.276 x 790.866 pts Page_size
- 55 Downloads / 207 Views
PRECLINICAL STUDIES
Drug repurposing using transcriptome sequencing and virtual drug screening in a patient with glioblastoma Mohamed E. M. Saeed 1 & Onat Kadioglu 1 & Henry Johannes Greten 2 & Adem Yildirim 3 & Katharina Mayr 1 & Frederik Wenz 4 & Frank A. Giordano 5 & Thomas Efferth 1 Received: 24 September 2020 / Accepted: 19 November 2020 # The Author(s) 2020
Summary Background Precision medicine and drug repurposing are attractive strategies, especially for tumors with worse prognosis. Glioblastoma is a highly malignant brain tumor with limited treatment options and short survival times. We identified novel BRAF (47-438del) and PIK3R1 (G376R) mutations in a glioblastoma patient by RNA-sequencing. Methods The protein expression of BRAF and PIK3R1 as well as the lack of EGFR expression as analyzed by immunohistochemistry corroborated RNA-sequencing data. The expression of additional markers (AKT, SRC, mTOR, NF-κB, Ki-67) emphasized the aggressiveness of the tumor. Then, we screened a chemical library of > 1500 FDA-approved drugs and > 25,000 novel compounds in the ZINC database to find established drugs targeting BRAF47-438del and PIK3R1-G376R mutated proteins. Results Several compounds (including anthracyclines) bound with higher affinities than the control drugs (sorafenib and vemurafenib for BRAF and PI-103 and LY-294,002 for PIK3R1). Subsequent cytotoxicity analyses showed that anthracyclines might be suitable drug candidates. Aclarubicin revealed higher cytotoxicity than both sorafenib and vemurafenib, whereas idarubicin and daunorubicin revealed higher cytotoxicity than LY-294,002. Liposomal formulations of anthracyclines may be suitable to cross the blood brain barrier. Conclusions In conclusion, we identified novel small molecules via a drug repurposing approach that could be effectively used for personalized glioblastoma therapy especially for patients carrying BRAF47-438del and PIK3R1-G376R mutations. Keywords Drug repurposing . Precision medicine . Targeted chemotherapy . Virtual drug screening
Background Half of the brain tumors represent diffuse gliomas, and the World Health Organization (WHO) provided classification
* Thomas Efferth [email protected] 1
Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Staudinger Weg 5, 5512 Mainz, Germany
2
Heidelberg Clinics for Integrative Diagnostics, Heidelberg, Germany
3
Cell and Matrix Biology, Institute of Zoology, Johannes Gutenberg University of Mainz, Mainz, Germany
4
University Hospital Freiburg, Freiburg im Breisgau, Germany
5
Department of Radiation Oncology, University Hospital Bonn, Bonn, Germany
criteria to predict the clinical behavior of these neoplasms [1]. Glioblastoma is classified as grade IV/IV gliomas with specific characteristics, including high cellularity, cellular pleomorphism, nuclear atypia and necrosis [2]. Glioblastoma has a dismal prognosis despite aggressive treatment [2, 3]. Various genetic mutations and aberration have been identified in glio
Data Loading...
